Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10516283 | 0.87 | CYP1A2 (0.37) | CYP1A2CYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL11067331 | 0.86 | MEN1 (0.35) | PKMGPR35CYP1A2CYP2C9RAB9A | |
| SCHEMBL11072324 | 0.86 | CYP1A2 (0.30) | CYP1A2CYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL11074597 | 0.85 | LMNA (0.36) | CCNA2CDK2CCNA1GAANPC1 | |
| Hydrochloric Acid SCHEMBL11065854 | 0.85 | — | — | |
| SCHEMBL10513959 | 0.84 | LMNA (0.32) | GAA | |
| SCHEMBL11076161 | 0.84 | CYP1A2 (0.36) | GPR35CYP1A2CYP3A4GAACYP2C9 | |
| SCHEMBL11069754 | 0.83 | CSNK2A1 (0.33) | RXFP1NPC1 | |
| SCHEMBL10513044 | 0.83 | TTR (0.35) | RXFP1GPR35 | |
| SCHEMBL11073859 | 0.82 | AKR1B1 (0.42) | GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-4935435-A | Use of tetrazole derivatives | MAY & BAKER LIMITED (GB) | 1990-06-19 | — | — | US | claimed |
| EP-0337701-A2 | Use of tetrazole-5-carboxanilides in the treatment of transplant rejection or arthritic, autoimmune or connective tissue disorders | MAY & BAKER LIMITED (GB) | 1989-10-18 | — | — | EP | claimed |
| EP-0323885-A1 | New chemical process | MAY & BAKER LIMITED (GB) | 1989-07-12 | — | — | EP | claimed |
| US-4442115-A | ANTI-ASTHMA | MAY & BAKER LIMITED (GB) | 1984-04-10 | — | — | US | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2023-03-02 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| WO-2011089214-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
| US-4935435-A | Use of tetrazole derivatives | MAY & BAKER LIMITED (GB) | 1990-06-19 | — | — | US | disclosed |
| EP-0337701-A2 | Use of tetrazole-5-carboxanilides in the treatment of transplant rejection or arthritic, autoimmune or connective tissue disorders | MAY & BAKER LIMITED (GB) | 1989-10-18 | — | — | EP | disclosed |
| EP-0323885-A1 | New chemical process | MAY & BAKER LIMITED (GB) | 1989-07-12 | — | — | EP | disclosed |
| US-4442115-A | ANTI-ASTHMA | MAY & BAKER LIMITED (GB) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | PKM 1172/4885RXFP1 926/4885CCNA2 1957/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | PKM 2753/4885RXFP1 1544/4885CCNA2 1855/4885 |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, NCL, ABCB1 | PKM 2531/4885RXFP1 3974/4885CCNA2 1294/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | PKM 1172/4885RXFP1 926/4885CCNA2 1957/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | PKM 2753/4885RXFP1 1544/4885CCNA2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.